BTIG Reiterates Buy Rating on Spyre (SYRE)

March 31, 2026 5:18 AM

BTIG analyst Julian Harrison reiterated a Buy rating and $70.00 price target on Spyre (NASDAQ: SYRE).The analyst comments "Royalty Pharma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found